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Abstract: Spinal cord injury (SCI) is a devastating disease, which leads to paralysis and is associated 
to substantially high costs for the individual and society. At present, no effective therapies are 
available. Here, the use of mechanically-activated lipoaspirate adipose tissue (MALS) in a murine 
experimental model of SCI is presented. Our results show that, following acute intraspinal MALS 
transplantation, there is an engraftment at injury site with the acute powerful inhibition of the 
posttraumatic inflammatory response, followed by a significant progressive improvement in 
recovery of function. This is accompanied by spinal cord tissue preservation at the lesion site with 
the promotion of endogenous neurogenesis as indicated by the significant increase of Nestin-
positive cells in perilesional areas. Cells originated from MALS infiltrate profoundly the recipient 
cord, while the extra-dural fat transplant is gradually impoverished in stromal cells. Altogether, 
these novel results suggest the potential of MALS application in the promotion of recovery in SCI.  




Spinal cord injury (SCI) is a devastating disease mainly caused by high-energy trauma. Patients 
with SCI always suffer from paralysis, locomotor and sensory dysfunction, urinary incontinence, or 
gastrointestinal dysfunction [1]. The impairment and disability derived from SCI leads to enormous 
personal suffering and substantial costs to society [2–4], with an incidence of 27–83 per million in the 
US and 10–30 per million in Europe [5,6]. In addition to the acute traumatic mechanical injury, there 
is the activation of secondary neurodegenerative mechanisms leading to the final damage of the cord 
[4,7–9]. There is currently no curative therapy, and in the acute phase, the intervention is often limited 
to surgical stabilization and decompression with possible high-dose corticosteroid treatment [3,10]. 
The use of acute erythropoietin was suggested, and recent small studies are suggestive of possible 
positive outcomes [11–13]. Many different approaches had been developed with unfortunately poor 
clinical outcomes [14], and even cellular and embryonic tissue transplantation were suggested and 
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studied for a long time with the aim to improve recovery of function through the partial replacement 
of neural tissue loss or the creation of a favorable environment for survival to injury and regrowth 
[13–19]. Up to now, no favorable clinical results are known and long-term safety remains a 
significantly open unmet medical need [16–18,20,21]. Curtis and coworkers [18] recently conducted 
a one-year long phase I trial in six patients with subacute spinal cord injury. This work showed that 
one year post-transplantation, there were no surgical, medical, or neurological complications in 
treated patients, thus indicating that the timing or procedure for the cell transplantation was safe. 
Until now, no positive clinical outcomes could be observed and this is a highly limiting step for the 
suggested therapy. Adipose tissue is a source of adult stem cells that show neuronal markers [22,23]. 
The advantages of using subcutaneous adipose tissue in comparison to other mesenchymal stem cell 
(MSC) sources have recently been investigated and confirmed. Indeed, this tissue can easily be 
accessed with low patient discomfort and the isolation of stem cells from it requires simpler and more 
efficient procedures [24]. It was suggested that implantation of adipose tissue-derived cells promoted 
functional recovery and revascularization in experimental spinal cord injury [25,26]. We recently 
demonstrated that the application of mechanical forces to the adipose tissue abolishes the 
inflammatory properties of fat and favors the expression of anti-inflammatory cytokines, such as 
TNF-alpha stimulated gene-6 (TSG-6) [23], which has been shown to exert protective effects in disease 
experimental models [27]. The mechanical activation of the adipose tissue could promote post-
translational pathways implicated in mechano-transduction [28]. Indeed, stretch-activated ion 
channels, growth factors, cytoskeleton filaments, focal adhesions, and tyrosine kinases, could all be 
involved in the translation of signals from mechanical forces into biochemical events, with 
downstream signals communicating key messages to the nucleus and subsequently altering gene 
expression [23,29–33].  
In the present study, we thus aimed to investigate the regenerative potential of the mechanically 
activated lipoaspirate adipose tissue (MALS) transplanted into the lesion epicenter in a murine 
experimental model of SCI, immediately after the contusion [13,15,34]. We show that MALS results 
engrafted two weeks after transplantation and promotes recovery of motor function, which is already 
evident at 24 hours after the insertion in the lesion site. The positive effects on functional recovery 
increases during the following days. This is associated with strong improvements in tissue 
preservation and counteraction of the local inflammatory response into the damaged spinal cord. We 
observe an increased number of cells positive to neuronal markers at the lesion site, where MALS has 
infiltrated. We hypothesize that the MALS convey for a sustained delivery of therapeutic agents that 
counteracts the acute local inflammatory response following spinal cord injury. We, thus, postulate 
that this allows a more delayed effect due to the synergic differentiation mechanism of ependymal 
stem cells. 
2. Materials and Methods 
2.1. Animal Care 
In this study, adult CD1 male mice 25–30 g in weight (Charles River, Calco, Italy) were used. 
The animals were kept in standard conditions (22 ± 2 °C, 65% humidity, and artificial light between 
8:00 a.m. and 8:00 p.m.) for at least three days before the experiments. All of the procedures were 
approved by the Review Committee of the University of Milan and met the Italian Guidelines for 
Laboratory Animals that gave its approval to the study (no. 3/2013), which conform to the European 
Communities Directive (2010/63/UE). 
2.2. Tissue Mechanical Activation 
Voluntary patients undergoing procedures of elective liposuctions were anesthetized locally 
with lidocaine (AstraZeneca, London, UK). The procedure requires an infiltration step, with the 
infusion of a solution of saline and epinephrine (2 μg/mL) (Key Customer Solutions S.A.S, Basiglio, 
Milan, Italy) into the adipose compartment. This leads to a minimization of blood loss and the 
reduction of infiltration by peripheral blood cells. From this procedure, it is possible to obtain a 
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particular kind of adipose tissue named lipoaspirate adipose tissue (lipoaspirate, LS) [23]. The 
activation of lipoaspirate has been performed as described in our previous paper [23]. Briefly, 10–15 
mL of lipoaspirated adipose tissue was activated by orbital shaking (97× g) for 10 min at room 
temperature. The product has been termed mechanically-activated lipoaspirate (MALS; WO 
2017/115289 Al). Elective liposuction procedures were performed in voluntary patients with full 
knowledge of the events. An informed consent was supplied and signed by each patient.  
2.3. Spinal Cord Injury, Setting of Experimental Animal Groups 
Traumatic SCI was performed in CD1 mice at the T8 level using a commercially available Infinite 
Horizon Impactor device (Precision Systems and Instrumentation, LLC, Lexington, KY, USA), as 
previously described and surgery on the animals was performed with minor modifications [34]. 
Briefly, animals were anesthetized for five minutes before the surgery with 2.5% isoflurane in oxygen 
(1 L/min; Farmagricola, San Donato, Milan, Italy). A dorsal vertical incision was made through the 
skin from T7 to T12 and the superficial fat pad was removed. The T7 and T10 bilateral paravertebral 
muscles were cut and a laminectomy was performed, exposing the spinal cord. The impactor tip was 
then positioned just above the cord and a force of 70 Kdyne was applied for 1 s to the spinal cord. 
After the contusion, LS or MALS tissue were immediately administered at the lesion site. Then, the 
muscles and the skin were sutured as previously reported [34]. Experimental animals groups were 
three: (1) lesioned mice (LES; n = 16), (2) lesioned mice transplanted with lipoaspirate (LS; n = 16) and 
(3) lesioned mice transplanted with mechanically-activated lipoaspirate (MALS; n = 16; [23]). 
2.4. RNA Extraction and Real Time-PCR 
Thirty-five days after transplant animals were sacrificed and cords were dissected for 
subsequence gene expression analysis (n = 6 mice for each group). Tissue homogenates were derived 
from five regions: the lesion epicenter and 1 cm and 2 mm both rostral and caudal to the lesion site 
[13,15]. The distance from the lesion was evaluated using a square ruler in order to always have a 
reproducible distance from the lesion epicenter and an analogous thickness of the tissue homogenate. 
Specifically, each biopsy was 1mm thick, starting to cut 0.5 mm below and finishing 0.5 mm above 
the desired site (e.g., setting 0 as the lesion epicenter, the central section was obtained sectioning −0.5 
mm and +0.5 mm from the lesion). The different areas were dissected out rapidly, frozen on dry ice, 
and stored at −80 °C until further processing. Total RNA was extracted using TRIZOL® reagent (Life 
Technologies, Carlsbad, CA, USA) following manufacturer’s instructions, quantified and processed 
as previously described [35,36]. Total RNA (1 μg) was reverse transcribed using iScript cDNA 
synthesis kit (Bio-Rad, Segrate, MI, Italy) and Real-Time PCR was performed with StepOnePlus™ 
Real-Time PCR System (Thermo Fisher, Waltham, MA, USA) using iQ SYBR Green Supermix (Bio-
Rad). Primers were designed using Oligo Perfect Designer Software (Life Technologies) and the 
sequences are reported in Table 1. Amplification conditions were as follows: AmpliTaq activation 95 
°C for 10 min; PCR denaturation step 95 °C for 15 sec; PCR annealing and elongation step 60 °C for 1 
min; 40 cycles of PCR were performed. Genes were quantified in triplicates, and 18S was used as 
housekeeping gene. Gene expression was calculated using the 2−ΔCt method. 
Table 1. Sequences of oligonucleotides used for mRNAs expression evaluation. 
Name Sequence 
m-IL1alpha F ATGGCCAAAGTTCCTGACTTGTTTGAAGAC 





m-IL1beta R  
 
CAGGTAGCTGCCACAGCTTCTCCACAGCCA 
m-IL6 F TCCAGTTGCCTTCTTGGGACTGATGCTGGT 
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m-IL6 R AGTTTCAGATTGTTTTCTGCAAGTGCATCA 
m-IL8 F GCTCCTGCTGGCTGTCCTTAACCTAGGCAT 
m-IL8 R ATTGGGCCAACAGTAGCCTTCACCCATGGA 
m-TNFalpha F GACGTGGAACTGGCAGAAGAGGCACTCCCC 
m-TNFalpha R GAGGCCATTTGGGAACTTCTCATCCCTTTG 
m-18S F TTTTCGGAACTGAGGCCATG 
m-18S R TGGCAAATGCTTTCGCTCTG 
2.5. Behavioral Tests and Hind Limb Function 
Functional recovery evaluations were assessed in a blinded fashion as described by Basso and 
co-workers [37]. Neurological function was evaluated first 24 h after injury and then twice a week for 
four weeks. Locomotor function and hind limb recovery after contusion were evaluated with the 
open field test according to the Basso mouse rating scale. The methods used are well known in the 
field of behavioral evaluation of recovery of function after SCI [37]. For behavioral experiments 10 
animals for all experimental groups were used: contusion 70 Kdyne; contusion 70 Kdyne + 
lipoaspirate (LS); contusion 70 Kdyne + mechanically-activated lipoaspirate (MALS).  
2.6. Immunohistochemistry and Quantitative Analysis 
Immunohistochemistry was carried as previously reported [38]. Briefly, tissues were formalin-
fixed and paraffin-embedded. A cryostat (set at −28 °C) was used to cut serial coronal sections (18 
μm) of the spinal cord (Leica, Buccinasco, MI, Italy) at −28 °C. Sections were rinsed twice in 0.1 
mol/mL PBS and then incubated in 3 g/L hydrogen peroxide diluted in 0.1 mol/L PBS for 15 min. This 
was done in order to block the endogenous peroxidase activity. Sections were washed twice more in 
0.1 mol/L PBS and then blocked in 1 g/L normal goat serum dissolved in 0.1 mol/L PBS for 1 h. The 
sections were then incubated with antibodies specific for nestin (1:200; Millipore, Burlington, MA, 
USA), beta-tubulin III (beta-tub III; 1:500; Covance, Princeton, NJ, USA), Map2 (1:200; Millipore), 
GFAP (1:1000; Covance), CD68 (1:200; Abcam, Cambridge, UK) in 0.1 mol/L PBS overnight at +4 °C. 
Sections were washed three times in 0.1 mol/L PBS, and then incubated for 1 h in anti-rabbit and anti-
mouse antibody (1:200), diluted in 0.1 mol/L PBS. The antigen-antibody complex was revealed with 
the avidin-biotin complex method using as chromogen the 30,30-diaminobenzidine (Sigma Chemical. 
Co., St Louis, MO, USA) and 0.01 g/L hydrogen peroxide in 0.1 mol/L PBS. When the product turned 
dark brown the reaction was arrested by washing with PBS. Sections incubated without primary 
antibody were used as negative control and they did not show any detectable immunoreactivity.  
Immunofluorescence analysis was also performed on 20 μm coronal sections obtained as above 
using a cryostat set at −28 °C (Leica). Slides were rinsed with PBS and treated with blocking solution 
(10% NGS, 0.2% Triton X-100) as previously described [13,39]. The following primary antibodies were 
used: MBP (1:500; Millipore), DCX (1:200; SantaCruz, Dalls, TX, USA) Adiponectin (1:50; Abcam), 
Leptin (1:200; Abcam). The secondary antibodies used were: 546 goat anti-rabbit IgG (1:200; Alexa, 
Thermofisher, Waltham, MA, USA), 546 donkey anti-goat IgG (1:200; Alexa), 488 goat anti-rat IgG 
(1:200, Alexa), 488 donkey anti-rabbit IgG (1:200, Alexa). Images were acquired using standardized 
confocal microscopy (Leica SP2 confocal microscope with He/Kr and Ar lasers). The ImageJ software 
(NIH. Bethesda, MD, USA) was used for microphotographic digital analysis [13,39,40]. The positive 
pixels were quantified against versus the negative background eliciting an index score, which 
includes fibers and neuronal [13]. The microscope light intensity of the laser was the same for all 
sections analyzed and for determining the background optical density. For the quantification of 
positive cells, the number of cells positive to the staining was counted with respect to the total nuclei 
number. This was done by means of ImageJ software following an already-described protocol [41]. 
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2.7. Fluoro-Ruby Protocol 
Fluoro-Ruby is a fluorescent rhodamine-conjugated dextran, widely used in literature, and 
already previously used by our group, to study in vivo axonal transport within the central nervous 
system (CNS) [13,42]. The preparation of the Fluoro-Ruby (Millipore) solution was done as 
previously described [13]. Fluo-Ruby was administered with an intraspinal injection at the level of 
the dorsal funiculus rostral to the lesion epicentre, at T6/T7 using a 5 μL Hamilton microsyringe 25 
days after treatment. Injection volumes ranged from 0.5–1 μL and the injections were gradually 
performed over a period of 10–15 minutes [13]. The animals were then allowed to recover and 
perfused 10 days after the tracer injection. The perfusion was done with neutral buffered 
formaldehyde as previously described. The spinal cord was then removed, post-fixed overnight in 
the same fixative solution, and then included in OCT (Killik Bio-Optica, Milano, Italy). The cords 
were then sectioned by means of a microtome (Zeiss, Oberkochen, Germany) cutting sections 18 μm 
in thickness. This analysis was performed on 3 animals per experimental group: 1) lesioned mice, 2) 
lesioned mice transplanted with LS, and 3) lesioned mice transplanted with MALS. 
2.8. BrdU Labeling 
BrdU was administered intraperitoneally at 3 μL/g body weight from a stock solution of 15 
mg/ml BrdU (Sigma-Aldrich, St.Louis, MO, USA) following manufacturer’s instructions and 
previously reported methods [43]. The injection was performed 25 days after treatment and animals 
were perfused 10 days after BrdU injection with neutral buffered formaldehyde as previously 
reported. The spinal cords were then removed, post-fixed overnight in the same fixative solution and 
included in OCT (Killik Bio-Optica). The cords were then sectioned by means of a microtome (Zeiss) 
with thickness set at 18 μm. Paraformaldehyde-fixed sections were denatured in 4 N HCl (15 min), 
neutralized in 100 mM sodium tetraborate pH 9.0 (15 min) and stained with monoclonal BrdU 
antibody (1:100, Abcam) overnight at 4 °C. The next day they were washed with PBS three times for 
5 min each, the slides were incubated with AlexaFluor 488 conjugated anti-rat IgG antibody (1:100, 
Jackson Immunoresearch, West Grove, PA, USA) for 2h at RT. The ImageJ software was used for 
microphotographic digital analysis [13,39,40]. The positive pixels were quantified against versus the 
negative background eliciting an index score, which includes fibers and neuronal [13]. The 
microscope light intensity of the laser was the same for all sections analyzed and for determining the 
background optical density. This analysis was performed on three animals per experimental group: 
(1) not treated lesioned mice (LES); (2) lesioned mice transplanted with LS; and (3) lesioned mice 
transplanted with MALS. 
2.9. Statistical Analyses 
Data were expressed as mean ± S.D. Multiple group’s comparison were made by one-way 
ANOVA followed by Bonferroni’s multiple comparisons test to assess statistical significance versus 
respective control. In prospective analysis (time) of animals’ recovery of function, data were 
compared with two-way ANOVA test. The analyses were performed using Prism 5 software 
(GraphPad Software Inc., La Jolla, CA, USA.) assuming a p value less than 0.05 as the limit of 
significance. 
3. Results 
3.1. Mechanically Activated Lipoaspirate Engraftment Shows Anti-Inflammatory Properties in Spinal Cord 
Injury 
It is now established that the therapeutic effect of stem cells can consist in them exerting a potent 
effect of counteracting neuroinflammation [13,15,23,44]. We, thus, aimed at investigating the anti-
inflammatory properties of Mechanically Activated Lipoaspirate (MALS) at the lesion site of Spinal 
Cord Injury (SCI). We assayed the expression of pro-inflammatory cytokines, which represent the 
major targets of pharmacological agents aimed at taming the inflammatory response in 
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neurodegenerative disorders. The mRNA levels of IL-1 alpha, IL-1beta, TNF-alpha, IL6, and IL-8 
were assayed by real time-PCR and their expression levels were compared between lesioned mice 
(LES), lesioned mice transplanted with lipoaspirate (LS), and lesioned mice transplanted with 
mechanically-activated lipoaspirate (MALS). Thirty-five days after contusion LES-, LS-, or MALS- 
transplanted animals were sacrificed (see Section 2 for details) and a small biopsy (1 mm) was micro-
dissected from the following different five areas of the spinal cord: 1 cm and 2 mm rostral and caudal 
to the lesion site and the lesion epicenter (please see the schematic in Figure 1). In all investigated 
biopsies, the assayed chemokines resulted decreased in the cord of the lesioned animals treated with 
MALS respect to both the control untreated lesioned mice (LES) and LS treated mice. This effect is 
significantly evident in the epicenter and caudal area of the transplanted cord. In particular, IL-1 
alpha was reduced in the epicenter and 2 mm caudal to the lesion site, whereas IL-1 beta and TNF-
alpha were decreased in all areas analyzed. IL-6 was reduced 1cm and 2 mm rostral to the lesion site 
and 2 mm caudal to the lesion site. IL-8 was reduced in the epicenter of the lesion and 2 mm caudal 
to the lesion site (Figure 1). Concordantly with these data, a decrease of CD68 positive cells was 
observed at the lesion site in MALS treated mice, suggesting a decreased macrophage infiltration 
(Figure S1). Together, the results indicate that MALS protects the contused spinal cord by inhibiting 
the expression of pro-inflammatory cytokines. 
 
Figure 1. MALS tissue administration reduces the expression of pro-inflammatory cytokines. 35 days 
after transplantation, mRNA levels of IL-1 alpha, IL-1 beta, TNF-alpha, IL-6 and IL-8 were quantified 
at the lesion epicenter and 2 mm and 1 cm caudal and rostral to the lesion site of animals transplanted 
with Mechanically activated lipoaspirate (MALS), or with lipoaspirated tissue (LS) or in lesioned non- 
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treated animals (LES). 18S was used as housekeeping gene. The evaluation was performed in triplicate 
on six different spinal cord samples for each condition. The data reported in the histogram are 
expressed as mean ± SD and statistical analysis was performed with Student’s t-test (n = 6). ***p < 
0.001; ** p < 0.01; * p < 0.05 vs. LES. ### p < 0.001; ## p < 0.01 vs LS . 
3.2. Lipoaspirate and MALS Engraftment Improve Recovery of Hind Limb Function.  
The evaluation of hind limb function recovery performed by open field locomotion test, Basso 
Mouse Scale (BMS; Figure 2) [37]. All animals involved in the study, tested the day prior to the 
contusion, obtained the top score (nine points) in the BMS scale. The 70 Kdyne traumatic impact on 
the spinal cord caused a loss of ability in hind limb function of lesioned mice, which was followed by 
a progressive gradual recovery reaching its maximum in five weeks (2.60 ± 0.32 points of the BMS 
scale; n = 10) in complete accordance with previously published results [13,15] (Figure 2). This 
corresponds to plantar placing of the paw with or without weight support or occasional, frequent, or 
consistent dorsal stepping, but no plantar stepping [37]. When animals were transplanted with 
lipoaspirate adipose tissue (LS), their recovery was significantly better than the LES group already at 
seven days, and reach a BMS score of up to 3.6 ± 1.1 points on the BMS scale at day 35 after 
transplantation (n = 10). This corresponds to occasional plantar stepping. After MALS engraftment, 
the functional recovery improved even more, starting to be significant already the day after 
transplantation (Figure 2). The behavioral improvement was particularly evident between days 7 and 
14 after SCI, and ameliorated again from 14 days after SCI until the end of the observational period 
(35 days). At this time point, the BMS score significantly improved for the MALS transplanted 
animals up to 5.70 ± 0.37 points, which corresponds to frequent or consistent plantar stepping, some 
coordination, and paws parallel at initial contact (Figure 2 and Table S1).  
 
Figure 2. MALS promotes recovery of hind limb function. The evaluation of hind limb motor 
functional recovery was determined by the open field locomotion test [37]. Lesioned mice showed a 
remarkable and long-lasting improvement when treated with MALS. The groups were randomized, 
and the analysis was performed in double-blind fashion. Values represent mean ± SD (n = 10). 
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Statistical differences were evaluated by means of two-way ANOVA test followed by Bonferroni’s 
post-test. *** p < 0.001; * p < 0.05 versus LES (lesioned untreated mice); °°° p < 0.001; ° p < 0.05 versus 
LS (lesioned mice treated with lipoaspirate). 
3.3. MALS Engraftment Promotes White Matter Sparing  
Myelin basic protein (MBP) is a fundamental factor present in the myelin-proteolipid shell of 
axons of oligodendrocytes and Schwann cells in the nervous system. In order to investigate the effect 
of MALS transplantation on white matter preservation, we stained spinal cord slices with the MBP 
antibody. We observed an increase in the MBP staining in LS and even more in the MALS treated 
mice, suggesting the counteraction of myelin loss and the maintenance of possible supportive 
elements for neuronal regeneration at the lesion epicenter (Figure 3). By using the staining for this 
marker, we evaluated the amount of myelin fibers, which appear to be increased significantly in LS 
treated mice with respect to controls, and even more so in MALS treated mice. Considered all 
together these evidences indicate cellular presence neighboring the lesion site, suggesting white 
matter sparing. 
 
Figure 3. Protective action of MALS on myelin sparing in the injured cord. The image shows the 
protective action of MALS tissue in the epicenter of the injured cord (please see schematic 
representation). After animal perfusion, spinal cords were dissected, postfixed, and longitudinally 
sectioned by means of a cryostat. Spinal cord tissue sections were stained for myelin basic protein 
(MBP, green). The confocal microscope images for the spinal cord of lesioned animals and 
transplanted with LS or MALS tissue were obtained using the same intensity, pinhole, wavelength, 
and thickness of the acquisition. Scale bar: 100 μm. The graph reported shows the quantification of 
fluorescence with reference to MBP staining. Data is expressed as mean of twelve different ﬁelds (n = 
4 mice; 3 ﬁelds/mouse for each condition). Values represent mean ± SD. We determined the statistical 
differences by means of one-way ANOVA test followed by Bonferroni’s post-test. *** p < 0.001; *p < 
0.05 vs. LES; ### p < 0.001 vs. LS. 
3.4. MALS Engraftment Promotes Both BrdU Incorporation and Neural Markers Immunoreactivity 
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The above results raised an important question: did we with the MALS treatment create 
favorable enough conditions for the neuronal differentiation of endogenous stem cells? Ependymal 
stem cells are the only cells retaining stem cell potential in the adult spinal cord [45] and it appeared 
important to investigate their presence after SCI. Moreover, the same area of the cord should be 
enriched in neuronal precursors. To investigate the influence of fat transplantation on neurogenesis 
we evaluated the incorporation of BrdU at lesion site, which was administered 25 days after tissues 
engraftment. Animals were sacrificed 10 days later (day 35 after treatment) and BrdU incorporation 
was evaluated by immunodetection with monoclonal antibody in coronal spinal cord sections. The 
number of proliferating cells resulted increased in the MALS treated animals compared with LS or 
lesioned not treated animals (Figure 4A). This indicates that there is a higher number of proliferating 
cells in mice treated with MALS. Furthermore, we investigated the expression of neuronal markers 
beta-tubIII and MAP2 by BrdU labeled cells (Figure 4B). BrdU positive cells result highly positive to 
the expression of beta-tubIII and MAP2 markers (>70%), suggesting that MALS may promote the 
differentiation of newly generated cells towards also neuronal phenotype.  
 
Figure 4. Transplanted MALS promotes an increase of BrdU labeled cells positive to neuronal 
markers. (A) The images show the BrdU positive cells (green) at the lesion epicenter (please see 
schematic representation) of contused not treated animals (LES), contused animals treated with 
lipoaspirate tissue, or contused animals treated with MALS tissue. Nuclei are stained with DAPI. The 
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confocal microscope images for the spinal cord of the three groups were obtained using the same 
intensity, pinhole, wavelength, and thickness of the acquisition. Scale bar 20 μm. The graph reported 
shows the quantification of fluorescence with reference to BrdU staining. Data is expressed as mean 
of nine different ﬁelds (n = 3 mice; 3 ﬁelds/mouse for each condition). Values represent mean ± SD. 
We determined the statistical differences by means of one-way ANOVA test followed by Bonferroni’s 
post-test (*** p < 0.001 vs. LES; ### p < 0.001 vs. LS). (B) Spinal cord sections of MALS treated animals 
labelled with BrdU (green) were counterstained with anti-beta-tubIII or anti-Map2 antibodies (in red). 
The graph shows the percentage of BrdU-positive cells expressing the above neuronal markers. Data 
is expressed as mean of nine different ﬁelds (n = 3 mice; 3 ﬁelds/mouse). Values represent mean ± SD. 
Longitudinal spinal cord sections containing the ependymal canal were evaluated for the 
expression of nestin (Figure 5, Figure S2) and doublecortin (DCX) as marker of early neuronal 
differentiation (Figure 6). In the group of mice treated with MALS, all the investigated areas of the 
cords (the epicenter, 2 mm rostral and 1 cm caudal) resulted highly positive to nestin staining, and 
the marker resulted more abundantly expressed in MALS compared to LES animal group (Figure 5). 
The magnification of the ependymal canal, kept caudally to the lesion site (please see Figure S2), 
shows that more stem cells are stimulated to growth and regenerate the area after SCI (Figure 5; 
Figure S2).  
 
Figure 5. MALS engraftment leads to increased neurogenesis in the grafted cord. The image shows 
an increase in neural precursor cells at the lesion site of MALS transplanted animals, as demonstrated 
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by the increase in Nestin positive cells. The graph reported shows the quantification of the 
distribution of Nestin’s expression along the grafted cord. Data is expressed as mean of twelve 
different ﬁelds (n = 4 mice; 3 ﬁelds/mouse). Values represent mean ± SD. We determined the statistical 
differences by means of ANOVA test followed by Bonferroni’s post-test. *** p < 0.001 vs. LES; °° p < 
0.01 of LES caudal vs. LES epicenter. Symbols ($;°;*) indicate the corresponding area in Figure S2. 
Doublecortin (DCX) is a microtubule associated protein expressed by neuronal precursors and 
immature neurons in embryonic and adult central nervous system, and neural precursors express 
DCX while actively dividing [46,47]. To further support the above evidence on MALS tissue’s 
protective effect on the degenerating spinal cord, cryostat sections of spinal cord of the three 
conditions (LES; LES+LS; LES+MALS), taken at 2 mm rostral and caudal to the lesion epicenter and 
in the center of the lesion, were examined for DCX expression 35 days after transplant (Figure 6). The 
immunoreactivity for DCX resulted increased in LS treated spinal cords and was noticeable at the 
lesion epicenter (Figure 6). MALS treated spinal cords resulted highly positive the DCX staining in 
the area of lesion epicenter and caudally, where it is especially concentrated in the ependymal canal. 
Spinal cords from lesioned not treated animals showed a very low positivity to the DCX staining 
(Figure 6). The quantification of DCX expression was performed and the graph shows a significant 
increase caudally to the lesion epicenter in spinal cords of MALS treated animals (Figure 6, Figure 
S3).  
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Figure 6. MALS tissue promotes re-growth of neurons. Spinal cord longitudinal sections were 
examined for DCX (red) expression 35 days after MALS transplant. Scale bar: 100 μm. The graph 
shows the quantification of positive cells (percentage) in sections taken at the lesion epicenter, 2 mm 
rostral or caudal to the lesion epicenter (please see schematic representation). Values represent mean 
± SD. We determined the statistical differences by means of one-way ANOVA test followed by 
Bonferroni’s post-test. ** p < 0.01, *** p < 0.001 vs. LES, # p < 0.05, ## p < 0.01, ### p < 0.001 vs. LS. (n = 4 
mice; 2 sections/mouse; 3 fields/section area). 
The cresyl violet staining was applied to mark neuronal presence at the lesion site. Indeed, the 
staining highlights the presence of Nissl substance in the cytoplasm of neurons, and it is possible to 
appreciate how the staining is more evident in the epicenter of the animals transplanted with MALS 
respect to LES (Figure 7). This could suggest, after 35 days, an increase in the number of neurons 
present in animals treated with MALS, thus indicating an on-going regenerative process.  
 
Figure 7. MALS transplanted spinal cords show increased neuronal presence cresyl violet staining of 
the lesioned spinal cord. The staining shows the presence of Nissl substance in the cytoplasm of 
neurons, more abundant at the epicenter of animals transplanted with MALS respect to LES. Scale 
bar: 100 μm. The picture is representative of labeling performed in two different sections (n = 4 mice; 
2 sections/mouse for each condition). 
Moreover, 35 days post injury the areas around the epicenter resulted positive to the staining for 
beta-tubulin III, a marker of neurons’ microtubules in the central nervous system (Figure 8). The 
positivity to beta-tubulin III further supports the fact that MALS in transplanted mice promoted the 
differentiation of neuronal progenitors into neurons. 
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Figure 8. Spinal cords engrafted with MALS show neuronal presence at lesion site. The epicenter of 
the lesion and the surrounding areas (2 mm rostral and 2 mm caudal) were evaluated for the presence 
of neuronal markers expression beta-tub III. It is possible to appreciate beta-tub III positive cells in 
the analyzed regions. Scale bars: 100 and 50 μm. (n = 4 mice; 2 sections/mouse; 3 field/section). 
3.5. Fluoro-Ruby Labeling Highlights Axonal Regeneration in the Injured Cord 
To evaluate quantitatively anterograde axonal regeneration Fluoro-Ruby was injected in the 
rostral cord at T6/T7 level 25 days after injury and MALS or LS transplantation (see Section 2 for 
details; Figure 9) [48]. The animals were then sacrificed ten days after tracer injection. 35 days post 
injury, Fluoro-Ruby was picked up only by intact axons. Labelling occurred differently in the three 
conditions (Figure 9A). In lesioned animals, the tracer was picked up at the site of injection up to the 
lesion epicenter, confirming our previous observations [13]. In lesioned animals transplanted with 
LS, the uptake was present from the injection site to the epicenter of the lesion, and only slightly 
caudally to the lesion. On the contrary, in the group of animals treated with MALS the uptake was 
noticeable from the injection site to the caudal cord across the lesion epicenter (Figure 9A). In this 
case, it is possible to appreciate the highest number of labelled axons that cross the lesion epicenter. 
The quantification of Fluoro-Ruby labelled axons is reported in the graph and it shows a two-fold 
increase of axon labeling in the caudal cord proximal to the lesion (2 mm) of MALS-treated animals 
(Figure 9B).  
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Figure 9. In vivo axonal transport recovery. (A) Qualitative images of anterograde axonal transport 
35 days after contusion in lesioned non-treated animals (LES), or lesioned animals treated with LS 
and MALS. As described in Materials and Methods, Fluoro-Ruby was injected at T6/T7 25 days after 
lesioning and animal sacrificed 10 days later. Schematic reconstruction of spinal cord longitudinal 
sections of lesioned, lesioned + LS, and lesioned + MALS treated animals. Nuclei were stained with 
DAPI (blue). (B) The graph shows the quantification of fluorescence 2 mm rostral and caudal to the 
lesion and at the epicenter of the lesion. Quantification was performed in three animals per group 35 
days after lesion. Statistical differences were determined by means of one-way ANOVA test followed 
by Bonferroni’s post-test. *** p < 0.001 vs. LES; ### p < 0.001 vs. LS. 
There is also a presence of GFAP positive cells, which has a role in repair after CNS injury, 
contributing to the formation of a glial scar at the lesion site. The presence of GFAP positive cells at 
the lesion site of MALS treated mice (Figure 10) indicates the presence of a physiological scarring 
process, aimed at repairing and taming the damage of the injury.  
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Figure 10. Glial scarring at the lesion site. The epicenter of the lesion and the surrounding areas (2 
mm rostral and 2 mm caudal) were evaluated for the presence of GFAP. This indicates an ongoing 
scarring process. Scale bar: 100 and 50 μm. (n = 4 mice; 2 sections/mouse; 3 fields/section). 
3.6. MALS Engrafted Invades the Lesion Site in the Injured Spinal Cord 
Thirty-five days after contusion, we investigated the engraftment capabilities of MALS and LS 
tissues on recipient spinal cords. Both LS and MALS were found to be vital and resulted engrafted at 
lesion site (Figures 11–13). The MALS tissue seems to diffuse more efficiently through the injured 
spinal cord and a contact between the fat and the cord tissue is present. Figure 11 shows that the 
contact area between MALS and spinal cord is positive to two neural markers, Map 2 and beta-
tubulin III, which are present also in the fat tissue, thus suggesting a cross-talk between the two 
tissues.  
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Figure 11. Synergistic interaction between MALS tissue and surrounding spinal cord 
microenvironment. The contact area between the lesion site and the MALS tissue shows positivity for 
two neuronal markers: Map2 and beta-tubulin III. Scale bar 100 μm. (n = 4 mice; 2 sections/mouse; 3 
fields/section). 
The engraftment of LS and MALS tissues into the spinal cord-lesioned areas was investigated 
evaluating the presence of adiponectin and leptin. These hormones are mainly produced by the 
adipose tissue [49]. Figure 12 shows that adiponectin is present both in LS and MALS treated cords. 
In the case of LS engrafted cords, the staining is more limited to the lesion epicenter. Interestingly, in 
MALS engrafted cords, the distribution of the adiponectin staining is also appreciable 2 mm rostral 
and caudal to the lesion epicenter. The quantification reported in the graph shows the number of cells 
expressing adiponectin at the distribution of this marker is equal in this part of the injured spinal 
cord.  
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Figure 12. Engraftment of the LS and MALS tissue in the spinal cord-lesioned area. The images show 
the presence of adiponectin (red), a hormone typically produced by the adipose tissue. The staining 
was performed at the lesion epicenter and 2 mm caudal and rostral to the lesion site of animals 
transplanted with LS and MALS tissues. Scale bar: 100 μm. The graph reports the percentage of cells 
positive to the marker in the analyzed sections (please see schematic representation). Values represent 
the mean ± SD. We determined the statistical differences by means of ANOVA test followed by 
Bonferroni’s post-test * p < 0.05, *** p < 0.001 vs. LES; ## p < 0.01, ### p < 0.001 vs. LS. 
Differently from adiponectin, leptin is expressed mainly rostral to the lesion epicenter and at the 
lesioned site (Figure 13). These evidences are confirmed by the quantification reported in the graph 
showing the number of cells positive to the marker. The quantification of cells positive to the two 
adipose marker was also confirmed by the quantification of the fluorescence intensity (Figure S4). All 
these results together indicate the engraftment of adipose tissue in the cord injured site, and a 
potential cross-talk between the two different tissues.  
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Figure 13. Engraftment of the MALS tissue in the spinal cord-lesioned area. The images show the 
presence of leptin (green), hormone typically produced by the adipose tissue. The staining was 
performed at the lesion epicenter and 2 mm caudal and rostral to the lesion site of animals 
transplanted with LS and MALS tissue. Scale bar: 100 μm. The graph reports the percentage of cells 
positive to the marker 2 mm rostral or caudal to the lesion epicenter (please see schematic 
representation). Values represent mean ± SD. We determined the statistical differences by means of 
ANOVA test followed by Bonferroni’s post-test. * p < 0.05, *** p < 0.001 vs. LES; ## p < 0.01, ### p < 
0.001 vs. LS. 
4. Discussion 
In this study, we aimed at evaluating a novel approach for spinal cord repair that employs 
mechanically activated adipose tissue transplanted at the lesion site. We observed that adipose tissue 
engraftments possess the physical properties to serve as a natural, three-dimensional space-filling 
material remaining localized at the injury site [26]. Differently from certain artificial scaffolds, adipose 
tissue fragments are not fragile, and their handling is, thus, convenient, with the implant being easily 
fitted into and above cavity [26]. The effects of transplanted mechanically activated adipose tissue 
(MALS) at the lesion site of animals suffering from acute traumatic SCI is directed to control 
inflammation acutely enhanced by traumatic lesioning, and its effects are comparable to those 
Cells 2019, 8, 329 19 of 24 
 
observed with EPO and corticosteroids [11,50]. The mechanical activation is obtained by orbital 
shaking at 97× g for 10 min, as we previously reported this procedure develops high anti-
inflammatory properties in the fat with a decrease in pro-inflammatory agents’ expression [23]. 
Neuroinflammation is a physiologic response to SCI resulting in microglia activation, which secretes 
multi-functional immunoregulatory factors, most notably IL-1 alpha, IL-1 beta, and IL-6 families 
[13,15,51,52]. Neuroinflammation recalls into the cord inflammatory cells and increases permeability 
of the BBB [44,53–55]. The enhanced expression of anti-inflammatory cytokine TSG-6 exerts 
protective effects when administered in experimental diseases by reducing cytokine production and 
the invasion of infiltrating neutrophils and neutralizing CXCL8 [23,27]. Indeed, transplanted MALS 
downregulates alpha and beta IL-1, TNF-alpha, IL6, and IL8 mRNAs throughout the lesioned spinal 
cord. This corresponds also to the decrease of macrophages infiltration in the injury site. The 
transplanted MALS tissue survived in the lesion cord for a long time (35 days) in spite of the strongly 
unfavorable environment, that could have been modified by the taming of the inflammatory response 
and the release of anti-inflammatory molecules such as TSG6 [23]. These observations are in line with 
previous reports in which TSG6 produced by mesenchymal stem cells showed potent anti-
inflammatory action in different conditions, such as lung damage [56] and mild traumatic brain 
injuries [57]. 
After SCI, there is a loss of myelin and oligodendrocytes, with the apoptosis of the latter that 
may proceed for several weeks [16,58–62]. Myelin regeneration, the process by which transplanted 
cells produce myelin around axons that have lost their myelin sheaths, has been targeted as a 
mechanism to enhance recovery following SCI. In the present work, we observed a small increase of 
myelin basic protein (MBP) positive cells in LS-treated mice, which was far more pronounced in 
MALS-treated mice. This situation was also very evident in the lesion epicenter suggesting a 
profound effect on white matter sparing favoring both axon survival and regeneration of lesioned 
axons. The positive effect of MALS transplantation on stem cells in injured spinal cord is confirmed 
by the activation of cell proliferation. It was also observed that the activated fat affected profoundly 
the fate of endogenous stem cells present in the ependymal canal; these cells differentiate and grow 
greatly with MALS treatment. This activation is shown by the increase in cells with nestin and 
doublecortin expression. Doublecortin (DCX) is a microtubule associated protein expressed by 
neuronal precursor cells and immature neurons in embryonic and adult central nervous system. 
Neural precursors express DCX while actively dividing [46,47]. The immunoreactivity for DCX was 
present in numerous cells 2 mm rostral to the lesion epicenter and in the epicenter itself, and is 
especially concentrated in the cells surrounding the ependymal canal. We might argue that MALS 
exerted simultaneously a possible neuroprotective action allowing the structural preservation, and 
neo-formation of a favorable milieu. This is suggested by the higher preservation of neuronal markers 
such as Beta-tub III and Map-2 at the site of interaction between MALS and spinal cord.  
The age-dependent decline in axon regeneration in the adult mammalian CNS is accompanied 
by increased immunoreactivity to glial fibrillary acidic protein (GFAP), a marker for reactive 
astrocytosis. In some cases, cell therapies following SCI cause a modification of astrogliosis with a 
reduction of GFAP immunoreactivity [13,15,63,64], yet it is unclear if this event is correlated to the 
promotion of axonal growth. GFAP-positive reactive astrocytes in proximity to SCI lesion sites were 
described as an unfavorable substrate for axon growth that could also secrete growth-inhibitory 
molecules [65]. On the other, it was noted that the prevention of astrocyte scar formation does not 
promote axonal regrowth across lesion [66], and may even cause a reduction of regenerative axons 
[17]. Indeed, reactive astrocytes help restrict secondary damage by forming a compact scar protecting 
outside tissue from a non-neural lesion core rich in inflammatory cells and fibroblasts [65–67]. MALS 
causes a reduction of diffused GFAP in the lesion cord, and such a reduction correspond to sites were 
activated fat has infiltrated into the cord as shown by leptin and adiponectin cellular staining. This 
also corresponds to the increased ependymal cells activation shown by nestin and DCX positivity. 
These cells appear to migrate from the intact cord to the lesion epicenter. In addition, in the grey 
matter there may be the neoformation of neurons deriving from the activated ependymal cells, which 
form new neural aggregates in the gray matter close to the lesion epicenter.  
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In this study, we demonstrated for the first time that the treatment by the implant of 
heterologous adipose tissue with protective characteristics was possible and exerted a significant 
therapeutic effect when it was transplanted into mice affected by SCI. MSCs by definition must lack 
the expression of HLA II, which are responsible for the initiation of the immune response [68,69]. 
Moreover, the MSCs expression of soluble factor H, the complement regulatory proteins CD46, CD55, 
and CD59, allows MSC to be able to inhibit activation of the complement system to a certain extent 
[70,71].This, together with the strong anti-inflammatory properties of MALS [23] avoided the 
inflammatory reaction which would otherwise be obtained in heterologous transplantation. The 
therapeutic effect was evaluated by employing the open field locomotion test attributing a score to 
the motor function recovery according to the Basso Mouse Scale (BMS) [37]. Our lesioning paradigm 
is well consolidated [13,15,34]. Our contusion procedure does not completely severe the cord, and in 
addition to the lateral and ventral pathways there are channels of survived spinal tissue, but the post-
traumatic inflammation and hypoxia are favorable environment for secondary degeneration and 
render these portions a hostile milieu for axonal regrowth. It is, thus, conceivable that the prompt 
and rapid action of MALS renders these territories amenable to sustain neurogenesis as we report 
here. Betz and coworkers grafted adenovirus transduced fat to express BDNF and NT3 [26] reporting 
histological data suggesting the repair of damaged spinal cord injury. In our study, we report that 
the rapid attenuation of inflammatory process exerted by heterologous activated fat obtained by 
“minimal manipulation approach” [23] may be responsible of recovery of function. The previous 
work reported that genetically modified fat transplanted into injured spinal cord may counteract 
neuroinflammation [26]. Here we confirmed this suggested evidence by applying a more natural fat 
pad, and integrated the possible mechanism of action. Our data support the hypothesis that MALS 
favors neurogenesis. The distributions of both nestin and DCX staining through the spinal cord tissue 
near the lesion not only in the ependymal canal (neurogenic area) prompt us to suggest that MALS 
would functionally interact with the micro-environment of injured areas of the cord contributing to 
neurogenesis, not only in niches where neurogenesis occurs constitutively. This is supported also by 
the progressive morphological changes and by the expression of neuronal markers such as beta-
tubulin III and MAP2 near to the fat pad. It could be also plausible that MALS allows the migration 
of meningeal cells (nestin and DCX positive cells) to the spinal cord parenchyma for the promotion 
of the repair process [72]. This interesting hypothesis will need further investigation in order to be 
demonstrated in this context. 
The obtainment of MALS by a minimal manipulative approach has the positive characteristic of 
not modifying the original relevant characteristics of the tissue, especially the ones concerning its 
utility for reconstruction, repair and replacement surgery [73,74]. This tissue is not recognized as a 
medicinal product (drug), as there is only a minimal manipulation. Indeed, by definition, the 
international society of stem cell research (ISCCR) and the regulatory agencies (Food and Drug 
Administration and European Medicines Agency) consider cell therapy as a drug when there is more 
than a minimal manipulation of cells destined for application in a clinical setting or where the 
intended use of the cells is different to their normal function in the body [73–75]. Thanks to its 
obtainment with minimal manipulation, MALS can be highly useful in regenerative medicine.  
Together, these results demonstrate a strong potential for MALS in SCI, indicating a significant 
recovery of function likely due to a combined action of acute anti-inflammatory mechanisms and 
long-term stimulation of tissue regeneration, further studies are required to elucidate the 
mechanisms underlying their protective properties. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Table S1: Prospective 
analysis (time) of functional recovery promoted by MALS. Figure S1: MALS engraftment counteracts 
macrophages invasion. Figure S2: neurogenesis shown in reconstructed picture of MALS grafted cord. Figure 
S3: quantification of fluorescence intensity for DCX immunoreactivity. Figure S4: quantification of fluorescence 
intensity for adiponection and leptin. . 
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